A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo:: The paradigm of glioblastoma multiforme treated by temozolomide

被引:45
作者
Stamatakos, Georgios S. [1 ]
Antipas, Vassilis P. [1 ]
Uzunoglu, Nikolaos K. [1 ]
机构
[1] Natl Tech Univ Athens, Sch Elect & Comp Engn, Inst Commun & Comp Syst, Lab Microwaves & Fiber Opt,In Silico Oncol Grp, GR-15780 Zografos, Greece
关键词
cancer; chemotherapy; chemotherapy optimization; glioblastoma multiforme; in silico oncology; Monte Carlo; neovasculature; patient individualized optimization; temozolomide; Temodal (TM); Temodar (TM); tumor growth; simulation model;
D O I
10.1109/TBME.2006.873761
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
A novel four-dimensional, patient-specific Monte Carlo simulation model of solid tumor response to chemotherapeutic treatment in vivo is presented. The special case of glioblastoma multiforme treated by temozolomide is addressed as a simulation paradigm. Nevertheless, a considerable number of the involved algorithms are generally applicable. The model is based on the patient's imaging, histopathologic and genetic data. For a given drug administration schedule lying within acceptable toxicity boundaries, the concentration of the prodrug and its metabolites within the tumor is calculated as a function of time based on the drug pharamacokinetics. A discretization mesh is superimposed upon the anatomical region of interest and within each geometrical cell of the mesh the most prominent biological "laws" (cell cycling, necrosis, apoptosis, mechanical restictions, etc.) are applied. The biological cell fates are predicted based on the drug pharmacodynamics. The outcome of the simulation is a prediction of the spatiotemporal activity of the entire tumor and is virtual reality visualized. A good qualitative agreement of the model's predictions with clinical experience supports the applicability of the approach. The proposed model primarily aims at providing a platform for performing patient individualized in silico experiments as a means of chemotherapeutic treatment optimization.
引用
收藏
页码:1467 / 1477
页数:11
相关论文
共 65 条
[1]  
Agarwala S S, 2000, Oncologist, V5, P144, DOI 10.1634/theoncologist.5-2-144
[2]   Temozolomide in combination with interferon α-2b in patients with metastatic melanoma -: A phase I dose-escalation study [J].
Agarwala, SS ;
Kirkwood, JM .
CANCER, 2003, 97 (01) :121-127
[3]  
[Anonymous], 2001, CHEMOTHERAPY SOURCE
[4]  
Baish JW, 2000, CANCER RES, V60, P3683
[5]   Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model [J].
Barbolosi, D ;
Iliadis, A .
COMPUTERS IN BIOLOGY AND MEDICINE, 2001, 31 (03) :157-172
[6]  
Bast R.C. Jr., 2000, HOLLAND FREI CANC ME
[8]  
Bobola MS, 1996, CLIN CANCER RES, V2, P735
[9]   CONTRIBUTION OF O-6-METHYLGUANINE-DNA METHYLTRANSFERASE TO RESISTANCE TO 1,3-(2-CHLOROETHYL)-1-NITROSOUREA IN HUMAN BRAIN TUMOR-DERIVED CELL-LINES [J].
BOBOLA, MS ;
BERGER, MS ;
SILBER, JR .
MOLECULAR CARCINOGENESIS, 1995, 13 (02) :81-88
[10]  
BRADA M, 1995, P AM SOC CLIN ONCOLO, V14